Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, Kato J, Ishikawa T, Doki N, Nakamae H, Maeda Y, Inamoto Y, Okada M, Maki A, Shimada F, Tajima T, Wroclawska M, Zeiser R, Onizuka M.
Teshima T, et al. Among authors: tajima t.
Int J Hematol. 2024 May 25. doi: 10.1007/s12185-024-03772-6. Online ahead of print.
Int J Hematol. 2024.
PMID: 38796666